Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.
Stocks · News reference
Akebia Therapeutics Initiates Phase 2 Basket Trial To Evaluate Safety, Efficacy, And Pharmacokinetics Of Ebribafusp For Treatment Of Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket trial to evaluate the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Dow up 100+ points. Western Digital falls after earnings beat expectations but lowers guidance. Other stocks dip in pre-market.
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser after CFO resignation.
Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $49.128 million which beat